Data Article

Genome sequence data announcement of *Bifidobacterium bifidum* strain ICIS-202 isolated from a healthy human intestine stimulating active nitrogen oxide production in macrophages

Oleg V. Bukharin, Sergey V. Andryuschenko*, Natalia B. Perunova, Elena V. Ivanova, Irina N. Chainikova, Irina A. Zdvizhkova

Orenburg Federal Research Center of the Ural Branch of the Russian Academy of Sciences, Institute for Cellular and Intracellular Symbiosis, Orenburg, Russia

**Abstract**

This report presents the data on the draft genome sequence of *Bifidobacterium bifidum* strain ICIS-202. The strain, isolated from the intestine of a young healthy woman, was deposited in the State Collection of Microorganisms of Normal Microbiota in Gabrichevsky Institute of Epidemiology and Microbiology, Moscow, Russian Federation as a prospective candidate for probiotic development. The size of the genome was 2,265,060 bp (62.4% G + C content). The annotation revealed 1771 coding sequences, including 1771 proteins, 5 rRNA, 52 tRNA, and 3 ncRNA genes. The draft genome sequence data of *B. bifidum* strain ICIS-202 is available in DBJ/EMBL/GenBank under the accession nos. SSMS00000000.1, PRJNA412271 and SAMN07709009 for Genome, Bioproject and Biosample databases, respectively.

© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

**Article Info**

Article history:
Received 28 May 2019
Received in revised form 22 October 2019
Accepted 30 October 2019
Available online 6 November 2019

Keywords:
WGS
Bifidobacterium
Nitrogen oxide
Cytokines
Human gut
Microbiocoenosis

**Abbreviations**

WGS: Whole Genome Sequence

https://doi.org/10.1016/j.dib.2019.104761

© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Bifidobacteria are predominant in the fecal microbiota of infants, and they are considered to be the most important physically and mentally beneficial bacteria for infants [1]. Infants with bifidobacteria-dominated gastrointestinal tracts are more resistant to colonization by pathogens, respond better to some vaccines, and possess better-functioning gut barriers [2–5]. Bifidobacteria also appears to enhance immune surveillance and reduce inflammation at the same time [5–8]. The presence of the infant-type bifidobacteria when the weaning takes place may help in guiding the immune system towards the tolerance during the introduction of new foods and their associated antigens, potentially influencing the development of allergic diseases [9–12]. Among other motivations, bifidobacterial levels have been studied in infants across the globe for these public health reasons.

The bacterial supernatant is a dynamic entity, which depends on many components and plays an essential role in immune response modulation. The aim was to investigate the bifidobacteria strain’s effect on phagocytic system cells (macrophages).

1. Data

The strain ICIS-202 was initially identified as B. bifidum with the biochemical species identification kit ANAEROtest 23 (Lachema, Czech Republic). It revealed, that the ICIS-202 strain ferments glucose, fructose, galactose, lactose, sucrose, raffinose, arabinose, urease and xylose. The disc diffusion test
revealed antibiotic resistance of the B. bifidum strain ICIS-202 to kanamycin, cefloxacin, ciprofloxacin, lomefloxacin.

We conducted studies on (CBAxC57B16)F1/c line mice 18–20 g in weight using the bacterial supernatant of B. bifidum strain ICIS-202. The macrophages, obtained from the mice’s peritoneal cavity, were individually cultivated with the B. bifidum strain ICIS-202’s culture medium supernatant for evaluation of its effect on nitric oxide production in the macrophages. The bifidobacteria’s supernatant displayed a stimulating effect on ability to produce NO/NO₂ of macrophages in vitro. Incubation of peritoneal macrophages with the bifidobacteria’s supernatant was accompanied by a moderate increase in the basic production of NO/NO₂ compared with the control. The effect of B. bifidum strain ICIS-202’s culture medium on nitrogen oxides and cytokine production by mouse macrophages is presented in Table 1.

2. Experimental design, materials and methods

Preparation of DNA libraries and sequencing were performed in the Center of Shared Equipment “Persistence of microorganisms” of the Institute for Cellular and Intracellular Symbiosis of the Ural Branch of the Russian Academy of Sciences (RAS; Orenburg, Russia).

The B. bifidum strain ICIS-202 was cultivated in 4 ml of Schaedler medium (HiMedia Laboratories Pvt. Limited) during 48 hours at 0.6% oxygen and 5% carbon dioxide atmosphere with temperature of 37 C in CO₂-incubator (BINDER, Tuttlingen, Germany). After incubation the culture was centrifuged at 4000 g for 6 min. The sediment was suspended again in 50 µl of tris-buffered saline with 2 µg of hen egg white lysozyme (HEWL), and then incubated at 37 C during 1 hour. After that, the suspension was mechanically homogenized by 1.4 mm silica beads at 6.5 m/s speed for 1 min. The DNAses were inactivated by heating the suspension up to 95 C for 10 minutes; then 50 µl of 10% SDS solution and 2 µl of 100 mg/ml proteinase K solution were added to the suspension with subsequent incubation at 60 C for 60 min. The extracted DNA solution was purified using the standard phenol-chloroform extraction method (6), and precipitated with ethanol (7). The DNA sediment was dissolved in 30 µl of «Milli-Q» deionized water.

Extracted DNA of the B. bifidum strain ICIS-202 was used to prepare a DNA library by using the Nextera XT DNA sample preparation kit (Illumina, San Diego, CA). The library was sequenced in a 2 × 300-nucleotide run using the MiSeq reagent kit version 3 and MiSeq desktop sequencer (Illumina). The reads were quality trimmed using the Trimmomatic program's sliding window mode (15). De novo genome assembly performed using the SPAdes genome assembler (St. Petersburg genome assembler, version 3.10.1) (8). The total of 2,265,060 bp with an N50 of 357,567, a G+C content of 62.4%, with an average coverage of 42.1. It was removed from the analysis. The genome sequence was annotated using the National Center for Biotechnology Information (NCBI) Prokaryotic Genome Annotation Pipeline (PGAP) (http://www.ncbi.nlm.nih.govgenome/annotation_prok), which revealed 1771 protein-coding gene sequences, 110 pseudogenes, 5 rRNA genes (5S, 16S, and 23S), 52 tRNA genes, and 3 noncoding RNA (ncRNAs) genes.

The culture medium’s supernatant of studying strain ICIS-202 was collected using high speed centrifugation (at 4000 g for 15 min) after incubation under the aforementioned conditions, and dialyzed on a 10 kDa membrane.

Nitrogen oxide production studies were performed on macrophages from mice strain (CBAxC57Bl6) F1/c, obtained from the animal nursery of the Branch “Stolbovaya” of the Scientific Center for Biomedical Technologies of the Federal Medical and Biological Agency of Russia. All studies were performed in complying with the European Convention’s rules for the vertebrates animals protection used for research and other scientific purposes (March 18, 1986) and the “Rules of laboratory practice in the Russian Federation” Order of the Ministry of Health of the Russian Federation N.267 dated June 19, 2003 [13]. The mice were injected intraperitoneally with sterile Brewer-thioglycollate medium (2 ml, 4% w/v) to recruit macrophages to peritoneal cavity. Four days after injection, the mice were sacrificed for macrophage collection from mouse peritoneal cavity using cold PBS. The cell pellets was obtained after centrifugation at 2000 rpm for 5 min. The cells will be incubated in DMEM supplemented with 10% FBS and 1% gentamicin (LLC RLS-Patent, Russia) for 2 h in CO₂-incubator (BINDER, Tuttlingen, Germany) and washed three times to remove non-adherent cells [14]. Isolated macrophages secreted
|                          | NO/NO₂, μmol/l | IFN-γ, pg/ml | TNF-α, pg/ml | IL-8, pg/ml | IL-1β, pg/ml | IL-10, pg/ml | IL-4, pg/ml |
|--------------------------|----------------|--------------|--------------|-------------|--------------|--------------|-------------|
| Peritoneal macrophages (control) | 55.8 (54.2–56.7) | 15.3 (14.9–15.6) | 13.8 (12.9–14.8) | 23.0 (21.2–25.1) | 88.8 (85.6–96.7) | 14.7 (12.2–16.7) | 0.7 (0.64–0.75) |
| Peritoneal macrophages + B. bifidum ICIS-202 culture medium (experimental) | 164.8 (160.2–177.4) | 30.8 (54.2–56.7) | 15.0 (14.2–15.6) | 22.7 (21.1–23.4) | 10.6 (8.5–13.2) | 45.6 (44.1–46.8) | 0.8 (0.72–0.86) |
high levels of IFN-γ, IL-8, TNF-α, IL-1β and low levels of IL-10, IL-4 which allowed them to be classified as pro-inflammatory macrophages (M1-like). Cytokine level in the cultural medium of the macrophages was determined by enzyme immunoassay by using the appropriate test systems (Bender MedSystems, Austria).

Macrophages were stimulated by culture medium’s supernatant B. bifidum strain ICIS-202 in the 1:100 cell ratio in 96-well plates for 24 hours at 37 C in an atmosphere of CO2 (5%). Upon finishing, supernatants were harvested and stored at −20 C.

The nitric oxide’s concentration level in the cultural medium of the macrophages was determined by test systems Total NO/Nitrite/Nitrate Assay (R&D Systems, Inc., USA). The differences between the control and test were considered statistically meaningful at p < 0.05.

Funding statement

This work was carried out in the framework of fundamental research at the Ural Branch of the Russian Academy of Sciences (project 18-7-8-34). The reported study was funded by RFBR according to the research projects 19-415-560002 and 18-34-00853.

Acknowledgments

We thank Andrey Plotnikov, Daria Poshvina and Yury Khlopko for technical assistance in the DNA library preparing and sequencing.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] T. Fujii, Y. Ohtsuka, T. Lee, T. Kudo, H. Shoji, H. Sato, S. Nagata, T. Shimizu, Y. Yamashiro, Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating smad7 expression in preterm infants, J. Pediatr. Gastroenterol. Nutr. 43 (2006) 83–88. https://doi.org/10.1097/01.mpg.0000228100.04702.f8.

[2] S. Fukuda, H. Toh, K. Hase, et al., Bifidobacteria can protect from enteropathogenic infection through production of acetate, Nature 469 (2011) 543–547.

[3] M.N. Huda, Z.T. Lewis, K.M. Kalanetra, et al., Does the intestinal bifidobacterial colonisation affect bacterial translocation? Anaerobe 14 (2008) 43–48.

[4] M.-B. Romond, M. Colavizza, C. Mullié, et al., Stool microbiota and vaccine responses of infants, Pediatrics 134 (2014) e362–e372.

[5] M. Chichlowski, G. De Lartigue, J.B. German, et al., Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function, J. Pediatr. Gastroenterol. Nutr. 55 (2012) 321–327.

[6] B. Shell, J. MacSharry, L. O’Callaghan, et al., Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice, Clin. Exp. Immunol. 144 (2006) 273–280.

[7] S. Tanabe, Y. Kinuta, Y. Saito, Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation, Int. J. Mol. Med. 22 (2008) 181–185.

[8] J. Preising, D. Philippe, M. Gleinser, et al., Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis, Appl. Environ. Microbiol. 76 (2010) 3048–3051.

[9] S.L. Young, M.A. Simon, M.A. Baird, et al., Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood, Clin. Diagn. Lab. Immunol. 11 (2004) 686–690.

[10] E.M. Brown, M.-C. Arrieta, B.B. Finlay, A fresh look at the hygiene hypothesis: how intestinal microbial exposure drives immune effector responses in atopic disease, Semin. Immunol. 25 (2013) 378–387.

[11] P.V. Kirjavainen, T. Arvola, S.J. Salminen, E. Isolauri, Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 51 (2002) 51–55.

[12] T. Enomoto, M. Sowa, K. Nishimori, et al., Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota, Allergol. Int. 63 (2014) 575–585.

[13] Rules of laboratory practice in the Russian federation. Order of the Ministry of health of Russian Federation No. 267, June 19, 2003.

[14] T. Thanh-Huyen, K. Swathi, M. Mansoor, MicroRNA-223 induced repolarization of peritoneal macrophages using CD44 targeting hyaluronic acid nanoparticles for anti-inflammatory effects, PLoS One 11 (5) (2016), e0152024, https://doi.org/10.1371/journal.pone.0152024. Published online 2016 May 5.